Fosun pharma (600196) announced on the evening of December 3 that the listing application for the Hans-like (also known as Sunitinib injection) developed by Henlius, in combination with pemetrexed and carboplatin, for the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with negative epidermal growth factor receptor (EGFR) gene mutations and negative anaplastic lymphoma kinase (ALK) has recently been approved by the National Medical Products Administration. In addition, the registration application for the peach blossom four-thing granules of the holding subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd. has recently been accepted by the National Medical Products Administration.